BioTech startup Synthace gets £7.3m Series A

Sep 20, 2017 · uktech.news

BioTech firm Synthace has raised £7.3m in Series A funding from investors including White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital.

Existing shareholders Sofinnova Partners, SOSV and Bioeconony Capital also participated.

The company, which has created proprietary language and software platform Antha specifically for biologists, says it will use the cash to gain further traction and expand in the market.

Antha, the company says, is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.

Synthace CEO Tim Fell said: "Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential."

Read Complete Article

RT @Startup_van: A very special evening at #behindthecurtain episode five! Two legends of the #fintech game @rickykno founder of @TandemMon…

RT @Chance2Shine: SHOT!!! @SadiqKhan is a very handy batsman 👏👏👏 New funding from @MayorofLondon will ensure many more children across th…

#TechX365: The UK raised over $2 billion in #venturecapital investment last quarter, but #Brexit remains a concern.… https://t.co/oOiiCnsl5q

Amazon's slew of new Echo, Alexa devices obscures new developer tools, features https://t.co/DhCskfaFDG by @ldignan

Unicorns! 👯 ☺ @browserlondon are looking for a Digital marketing manager https://t.co/a2HKERG1qb #marketing #analytics